Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Non-Current Debt data on file, last reported at $49.7 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $49.7 million, down 15.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.7 million (down 15.28% YoY), and the FY2025 annual result was $49.4 million, down 50.74% from the prior year.
• Non-Current Debt advanced to $49.7 million in Q1 2026 per LXRX's latest filing, from $49.4 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $100.3 million in Q4 2024 and troughed at $23.5 million in Q1 2022.
• A 5-year average of $66.8 million and a median of $56.5 million in 2025 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 317.98% in 2023, then slumped 50.74% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $48.6 million in 2022, then jumped by 104.84% to $99.5 million in 2023, then increased by 0.79% to $100.3 million in 2024, then sank by 50.74% to $49.4 million in 2025, then increased by 0.56% to $49.7 million in 2026.
• Business Quant data shows LXRX's Non-Current Debt at $49.7 million in Q1 2026, $49.4 million in Q4 2025, and $56.5 million in Q3 2025.